Show simple item record

dc.contributor.authorPratt, Gen_US
dc.contributor.authorYap, Cen_US
dc.contributor.authorOldreive, Cen_US
dc.contributor.authorSlade, Den_US
dc.contributor.authorBishop, Ren_US
dc.contributor.authorGriffiths, Men_US
dc.contributor.authorDyer, MJSen_US
dc.contributor.authorFegan, Cen_US
dc.contributor.authorOscier, Den_US
dc.contributor.authorPettitt, Aen_US
dc.contributor.authorMatutes, Een_US
dc.contributor.authorDevereux, Sen_US
dc.contributor.authorAllsup, Den_US
dc.contributor.authorBloor, Aen_US
dc.contributor.authorHillmen, Pen_US
dc.contributor.authorFollows, Gen_US
dc.contributor.authorRule, Sen_US
dc.contributor.authorMoss, Pen_US
dc.contributor.authorStankovic, Ten_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-03-02T14:58:37Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28643365en_US
dc.identifier.citationBr J Haematol, 2018, 182 (3), pp. 429 - 433en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1518
dc.identifier.eissn1365-2141en_US
dc.identifier.doi10.1111/bjh.14793en_US
dc.format.extent429 - 433en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectDNA damageen_US
dc.subjectchronic lymphocytic leukaemiaen_US
dc.subjectmantle cell lymphomaen_US
dc.subjectolapariben_US
dc.subjectAgeden_US
dc.subjectAtaxia Telangiectasia Mutated Proteinsen_US
dc.subjectDNA Damageen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cellen_US
dc.subjectLeukemia, Prolymphocytic, T-Cellen_US
dc.subjectLymphoma, Mantle-Cellen_US
dc.subjectLymphoproliferative Disordersen_US
dc.subjectMaleen_US
dc.subjectMaximum Tolerated Doseen_US
dc.subjectMiddle Ageden_US
dc.subjectPhthalazinesen_US
dc.subjectPiperazinesen_US
dc.subjectPoly(ADP-ribose) Polymerase Inhibitorsen_US
dc.subjectRecurrenceen_US
dc.subjectSurvival Analysisen_US
dc.subjectTumor Suppressor Protein p53en_US
dc.titleA multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bjh.14793en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBr J Haematolen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume182en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Trials & Statistics Uniten_US
dc.contributor.icrauthorMarsden,en_US
dc.contributor.icrauthorYap, Christinaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record